Core Insights - Premarket trading is showing notable activity with significant price movements indicating potential trading opportunities before the market opens [1] Premarket Gainers - TechCreate Group Ltd. (TCGL) is up 99% at $205.71 - VivoSim Labs, Inc. (VIVS) is up 74% at $2.96 - La Rosa Holdings Corp. (LRHC) is up 55% at $4.66 - Sandisk Corporation (SNDK) is up 23% at $668.13 - Springview Holdings Ltd (SPHL) is up 19% at $4.76 - BUUU Group Limited (BUUU) is up 16% at $10.86 - Deckers Outdoor Corporation (DECK) is up 11% at $111.64 - Lumentum Holdings Inc. (LITE) is up 10% at $419.58 - Chanson International Holding (CHSN) is up 10% at $2.15 - Century Therapeutics, Inc. (IPSC) is up 9% at $2.20 [3] Premarket Losers - Kaixin Holdings (KXIN) is down 43% at $5.70 - Brand Engagement Network, Inc. (BNAI) is down 32% at $35.56 - PennyMac Financial Services, Inc. (PFSI) is down 21% at $117.50 - Schneider National, Inc. (SNDR) is down 19% at $24.05 - Moolec Science SA (MLEC) is down 19% at $5.23 - Nuwellis, Inc. (NUWE) is down 18% at $3.43 - Digital Currency X Technology Inc. (DCX) is down 16% at $3.44 - Serina Therapeutics, Inc. (SER) is down 15% at $3.03 - Namib Minerals (NAMM) is down 11% at $5.00 - ZeroStack Corp. (ZSTK) is down 6% at $11.00 [4]

Core Insights - Premarket trading is showing notable activity with significant price movements indicating potential investment opportunities before the market opens [1] Group 1: Premarket Gainers - Smart Logistics Global Limited (SLGB) is up 198% at $3.67 [3] - Brand Engagement Network, Inc. (BNAI) is up 67% at $10.29 [3] - Boxlight Corporation (BOXL) is up 56% at $1.96 [3] - Moolec Science SA (MLEC) is up 51% at $6.64 [3] - Anteris Technologies Global Corp. (AVR) is up 15% at $6.63 [3] - Hycroft Mining Holding Corporation (HYMC) is up 10% at $47.20 [3] - Nathan's Famous, Inc. (NATH) is up 8% at $100.94 [3] - Progress Software Corporation (PRGS) is up 6% at $41.05 [3] - LightPath Technologies, Inc. (LPTH) is up 5% at $14.81 [3] - ZenaTech, Inc. (ZENA) is up 5% at $4.33 [3] Group 2: Premarket Losers - Top Wealth Group Holding Limited (TWG) is down 29% at $3.81 [4] - Solo Brands, Inc. (SBDS) is down 21% at $5.25 [4] - GlucoTrack, Inc. (GCTK) is down 19% at $3.07 [4] - Galaxy Payroll Group Limited (GLXG) is down 19% at $2.26 [4] - INVO Fertility, Inc. (IVF) is down 13% at $2.04 [4] - Black Titan Corporation (BTTC) is down 11% at $2.11 [4] - Envirotech Vehicles, Inc. (EVTV) is down 10% at $3.30 [4] - Erasca, Inc. (ERAS) is down 6% at $9.21 [4] - ENDRA Life Sciences Inc. (NDRA) is down 6% at $4.31 [4] - Bonk, Inc. (BNKK) is down 6% at $3.74 [4]

Core Insights - PainReform Ltd. announced a name change and is expanding into diversified healthcare and AI-driven energy platforms, resulting in a 27.4% increase in share price to $1.02 in pre-market trading [1] Gainers - Acco Group Holdings Limited saw a significant gain of 219.4%, reaching $9.40 in pre-market trading [4] - Venus Concept Inc. increased by 72.2% to $2.48 [4] - Jaguar Health, Inc. rose 41.3% to $1.08 following a licensing agreement with Woodward Specialty [4] - ImmunityBio, Inc. gained 22.8% to $4.85, with preliminary net product revenue for Anktiva projected at approximately $113 million for fiscal 2025, marking a 700% year-over-year increase [4] - OneMedNet Corporation rose 14.2% to $0.9711 after a previous decline [4] - Brand Engagement Network, Inc. increased by 13.8% to $6.50 [4] - Springview Holdings Ltd rose 13.4% to $19.75 after a substantial 657% increase on Thursday [4] - Creative Global Technology Holdings Limited gained 10.7% to $4.22 after a 52% jump on Thursday [4] - Kopin Corporation increased by 8.1% to $3.20 [4] Losers - Callan JMB Inc. fell 20.7% to $3.33 after a 275% increase on Thursday due to a strategic agreement with Biostax Corp [4] - Erayak Power Solution Group Inc. decreased by 18.3% to $3.21 after an 18% rise on Thursday [4] - TryHard Holdings Limited dropped 16.4% to $6.35 following a 76% decline on Thursday due to a joint venture announcement [4] - iOThree Limited shares dipped 15% to $2.56 [4] - NOVONIX Limited fell 14% to $1.17 [4] - Moolec Science SA tumbled 13.1% to $6.69 after an 118% increase on Thursday [4] - High Roller Technologies, Inc. declined 12.9% to $20.64 after a 25% rise on Thursday [4] - Bonk, Inc. fell 10.4% to $3.55 after a 42% increase on Thursday due to acquisition news [4] - J B Hunt Transport Services Inc fell 4.2% to $197.86, reporting mixed financial results for the fourth quarter [4] - QXO Inc dipped 3.5% to $24.14 after announcing a $750 million stock offering and preliminary fourth-quarter net sales of $2.19 billion [4]

Company Highlights - Ambitions Enterprise Management Co. L.L.C (NASDAQ:AHMA) saw its stock price rise to $28.03, marking an 80.88% increase, driven by strong performance in the MICE and tourism sectors [1][7] - authID Inc. (NASDAQ:AUID) experienced a stock price increase to $1.77, a 78.34% rise, reflecting the growing demand for secure, biometric identity verification solutions [2][7] - CALLAN JMB INC. (NASDAQ:CJMB) saw its stock price surge to $3.91, a 249.12% increase, as it shifts towards cold-chain infrastructure to support the $100 billion GLP-1 pharmaceutical market [3][7] - Moolec Science S.A. (NASDAQ:MLEC) experienced a 101.42% increase in its stock price to $7.11, indicating market interest in alternative protein sources and sustainable food technologies [4] - Springview Holdings Ltd (NASDAQ:SPHL) saw its stock price jump to $15.9, a staggering 606.67% increase, highlighting robust demand in the construction sector [5] Industry Trends - The movements in stock prices reflect diverse sectors experiencing growth, including technology, biotechnology, logistics, and construction, indicating broader economic trends and investor interests [6] - Strategic initiatives and partnerships by these companies demonstrate a proactive approach to capitalizing on market opportunities and addressing industry demands [6]

Group 1: Company Performance - Gelteq Ltd (NASDAQ:GELS) shares rose sharply by 50.1% to $1.25 in pre-market trading after reporting positive preclinical results for its cannabinoid oral gel delivery platform [1][2] - The proprietary oral gel platform achieved a greater than 22% increase in the bioavailability of cannabidiol compared to an existing FDA-approved oil-based product [1] Group 2: Other Notable Stock Movements - Inspire Veterinary Partners Inc (NASDAQ:IVP) gained 141.3% to $0.056 after filing a Certificate of Amendment to increase its authorized Class A common stock from 100 million to 700 million shares [5] - Oriental Culture Holding Ltd (NASDAQ:OCG) rose 40.8% to $0.016 following the board's approval of a special cash dividend of 5 cents per share [5] - XCF Global Inc (NASDAQ:SAFX) gained 30.2% to $0.22 after announcing expansion financing plans [5] - AiRWA Inc (NASDAQ:YYAI) rose 15.8% to $1.46 after a director purchased 1.109 million shares at an average price of $1.35 per share [5] - Autolus Therapeutics PLC (NASDAQ:AUTL) gained 7.3% to $1.47 after announcing preliminary fourth-quarter and FY25 revenue results [5] Group 3: Declining Stocks - Briacell Therapeutics Corp (NASDAQ:BCTX) fell 53.1% to $5.12 after announcing the pricing of a $30 million public offering [5] - Moolec Science SA (NASDAQ:MLEC) fell 19.8% to $3.94 after a previous jump of 19% [5] - Hub Cyber Security Ltd (NASDAQ:HUBC) fell 19.1% to $0.43 after gaining 56% on the previous day [5] - Trip.com Group Ltd (NASDAQ:TCOM) dipped 9.3% to $68.55 amid an investigation by China's SAMR for potential anti-monopoly violations [5]

Moolec Science SA (NASDAQ:MLEC) executed a reverse stock split at a 15-for-1 ratio, significantly reducing the total number of shares available.The reverse stock split adjusted the par value of each share from $0.10 to $1.50, with the current stock price marking an increase to $4.30.Following the reverse stock split, MLEC's market capitalization stands at approximately $3.12 million, aiming to stabilize the stock's performance and improve market perception.Moolec Science SA, listed on NASDAQ under the symbo ...

Group 1 - The company Moolec Science SA has completed a share consolidation at a ratio of 15-for-1, effective January 5, 2026 [1] - Following the consolidation, shareholders will hold 1 ordinary share of par value US$1.50 for every 15 ordinary shares of par value US$0.10 each they previously held [1] - The share consolidation was approved during an extraordinary general meeting of shareholders on December 16, 2025, and by the company's board of directors on December 19, 2025 [1]

Core Viewpoint - Moolec Science SA has announced a share consolidation with a final ratio of 15-for-1, effective January 5, 2026, to comply with Nasdaq listing requirements [1][4]. Share Consolidation Details - The share consolidation will reduce the number of issued and outstanding ordinary shares from 10,891,761 to approximately 726,118 shares [2]. - No fractional shares will be issued; any resulting fractional shares will be rounded up to the nearest whole share, ensuring no dilutive effect on shareholders [3]. Compliance and Trading Information - The consolidation aims to regain compliance with Nasdaq's minimum bid price requirement of U.S.$1.00 per share, as per Nasdaq Listing Rule 5550(a)(2) [4]. - The new shares will be admitted to trading on the Nasdaq Capital Market under CUSIP number G6223S 125 starting January 5, 2026 [4]. Company Overview - Moolec Science is focused on producing animal proteins and nutritional oils in plants, utilizing molecular farming and precision fermentation [6]. - The company has a diversified pipeline that includes alternative proteins, bioactive compounds, nutritional oils, and biological inputs for regenerative agriculture [6]. - Moolec holds over 118 granted and pending patents across multiple technology platforms, indicating a strong intellectual property portfolio [6].

Financial Viability and Risks - The company faces substantial doubt about its ability to continue as a going concern, as indicated in its financial statements for the year ended June 30, 2025[111]. - The company has a history of losses and may not achieve or maintain profitability, which increases investment risk[111]. - The company may require additional financing to achieve its goals, and failure to secure necessary capital could delay or limit operations[111]. - As of June 30, 2025, the company reported a working capital deficit of $204.9 million, raising substantial doubt about its ability to continue as a going concern[122]. - The net losses for the year ended June 30, 2025, were $154.6 million, with an accumulated deficit of $57.3 million[123]. - The company had $248.0 million in total indebtedness as of June 30, 2025, with 92% classified as current[134]. - Bioceres S.A. defaulted on a portion of its financial debt amounting to $36.4 million in June 2025, initiating a debt restructuring process[141]. - Bioceres LLC received a notice of default on its financial debt of $69.5 million, leading to the auction of pledged BIOX shares[141]. - The company may need to secure additional capital to fund its longer-term capital and liquidity needs, as it does not expect to rely solely on cash balances and operating cash flow[123]. Competitive Landscape - The company operates in a highly competitive environment, with many competitors having greater financial and technical resources[113]. - The competitive landscape includes companies with greater financial and technical resources, which may hinder the Company's ability to keep pace in product development and market presence[165]. - The company competes against larger, well-capitalized food and ingredients companies, limiting its success in brand awareness[196]. Product Development and Market Challenges - The company’s future revenue depends on the success of its technologies and product developments, including extrusion, fermentation, and molecular farming[111]. - The introduction and improvement of new products from the Company's development pipeline are critical for generating revenue and achieving market acceptance[169]. - Significant risks in product development include delays in market acceptance, regulatory approvals, and competition from superior products[172]. - The company faces challenges in scaling agricultural production due to climatic variability, cost overruns, and low farmer adoption of target crops[173]. - The potential size of target markets for products is significant, but estimates are based on unverified assumptions that may not prove accurate[175]. - Negative public perception of GMOs and molecular farming could adversely affect commercialization efforts and regulatory environments[177][180]. - Consumer preferences for plant-based proteins are difficult to predict, and shifts away from the company's products could harm sales and market share[181][183]. Regulatory and Compliance Issues - The company’s operations are subject to various risks, including regulatory changes and compliance with environmental laws[115]. - The company is subject to numerous laws and regulations, including data protection and anti-corruption laws, which could result in liability if not complied with[200][201]. - Regulatory changes in the U.S. and abroad could increase the time and costs associated with launching new products, adversely affecting operating results[254]. - The regulatory environment outside the U.S. is highly uncertain, which may limit the company's ability to expand into global markets[255]. - Compliance with environmental, health, and safety regulations could be costly and time-consuming, potentially impairing research and development efforts[260]. Intellectual Property and Legal Risks - The company relies on a combination of intellectual property protections, but these may not be sufficient to prevent disclosure or infringement[234]. - License agreements with third parties limit the company's rights to use certain important technologies, and termination of these agreements could adversely affect operations[238]. - The company faces significant risks related to its patent positions, which may adversely affect its competitive position due to the complexity and uncertainty of biotechnology patents[240]. - The company may not be able to adequately enforce its intellectual property rights in jurisdictions where it has sought protection, potentially limiting its commercial success[241]. - Changes in patent laws could allow others to use the company's discoveries without compensation, impacting its ability to secure patent protection[243]. - The company may incur substantial costs in enforcing its patent rights, which could divert resources from other business areas and affect its operations[244]. Market and Economic Conditions - Economic instability in Argentina, including high inflation and currency fluctuations, poses material risks to the company's financial condition[208]. - The recent presidential elections in Argentina resulted in a new government that may introduce significant economic changes affecting the company[210]. - The ambitious deregulation plan under Decree 70/2023 and the Bases Law could significantly affect the company's business and financial condition[217]. - The agricultural industry is susceptible to commodity price changes, which may negatively impact the company's ability to commercialize products[226]. - The company's operations may be adversely affected by climate change and adverse weather conditions, which can reduce crop size and quality[229]. - The company's sales and operating results are highly seasonal, influenced by planting and harvest seasons, leading to substantial fluctuations[230]. Corporate Governance and Compliance with Nasdaq - The company is currently listed on the Nasdaq Capital Market and faces substantial doubt about its ability to comply with continued listing standards, which require a minimum of $500,000 in net income from continuing operations or at least $2.5 million in stockholders' equity[277]. - The company's ordinary shares have been trading below the minimum requirement of $1.00 per share for 30 consecutive business days, which could lead to automatic delisting from Nasdaq[280]. - On November 14, 2025, the company received a determination letter from Nasdaq regarding its non-compliance with the minimum bid price requirement[281]. - The company has submitted an appeal to request a 180-day period to submit a compliance plan, which may include a reverse stock split[282]. - A reverse stock split with a ratio of fifteen-to-one has been approved by the board, expected to be effective around January 5, 2026, to increase the ordinary share price[284]. - The company has not filed its Annual Report on Form 20-F for the year ended June 30, 2025, leading to a compliance issue with Nasdaq Listing Rule 5250(c)(1)[287]. - The complexities arising from the business combination in mid-June 2025 have delayed the filing of the Form 20-F[288]. - The company is committed to monitoring the closing bid price of its ordinary shares and evaluating actions to regain compliance with Nasdaq listing rules[285]. - If the ordinary shares are delisted, they may trade in the over-the-counter market, which could significantly affect liquidity and market perception[290]. Operational and Management Challenges - The company faces difficulties in integrating acquired businesses and realizing anticipated cost savings and synergies[118]. - The reliance on third-party growers for seed production poses risks to the Company's supply chain and operational stability[163]. - Attracting and retaining qualified employees is critical for the company's growth and operational success[188]. - The company faces potential substantial damages from defective product lawsuits, which may not be covered by insurance[193]. - Limited brand awareness could hinder the company's ability to sell products effectively[194]. - Significant resources will be required for a marketing campaign to improve brand awareness and market position[195]. - Failure to develop technology and brand could adversely affect future growth and customer loyalty[197]. - The company is increasingly reliant on third-party information technology systems, exposing it to operational risks and potential cyber-attacks[198]. - The resignation of Nomura as the exclusive financial advisor may indicate reluctance to be associated with the company's disclosures and business analysis[274]. - The trading volume and price of Ordinary Shares could decline if analysts cease coverage or change their recommendations adversely[299].

Core Insights - The consumer staples sector is experiencing a trend of oversold stocks, presenting potential buying opportunities for undervalued companies [1] Group 1: Oversold Stocks - Nomad Foods Ltd (NYSE:NOMD) has an RSI of 23.8, with a stock price decline of approximately 13% over the past month, closing at $11.96 [8] - JBS NV (NYSE:JBS) has an RSI of 25.7, with a stock price decrease of around 19% over the past month, closing at $12.81 [8] - Moolec Science SA (NASDAQ:MLEC) has an RSI of 15.1, with a significant stock price drop of about 46% over the past month, closing at $0.68 [8] Group 2: Company Developments - Nomad Foods announced the appointment of Dominic Brisby as the new CEO, effective Nov. 3, following the tenure of Stéfan Descheemaeker [8] - JBS received an Overweight rating from Stephens & Co. analyst Pooran Sharma, maintaining a price target of $19 [8] - Moolec Science received regulatory approval in Argentina for its Safflower GLASO Technology and appointed Valeria Falottico as CFO, indicating progress in its operations [8]